吸入PEG-ADM在ARDS患者的安全性和有效性:一个随机对照试验
Christian Karagiannidis1, Danny F McAuley2, B Taylor Thompson3
1ARDS and ECMO Centre Cologne-Merheim, University Witten/Herdecke, Ostmerheimer Strasse 200, 51109, Cologne, Germany. Christian.Karagiannidis@uni-wh.de.
Critical care (London, England)
|October 23, 2025
概括
吸入的基化上腺素 (PEG-ADM) 对急性呼吸窘迫综合征患者是安全的,但没有改善临床结果. 该试验因徒劳而中止,没有显示显著的疗效益.
科学领域:
- 关键护理医学 关键护理医学
- 肺部病理学 肺部病理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 急性呼吸困扰综合征 (ARDS) 在重症监护中构成了重大挑战.
- 机械通风是ARDS患者常见的支持措施.
- 对ARDS管理的新型治疗剂的评估至关重要.
研究的目的:
- 评估ARDS重症患者吸入基化上腺素 (PEG-ADM) 的安全性和有效性.
- 确定PEG-ADM对无呼吸器生存率和其他临床效用指数的影响.
- 为ARDS管理中潜在的治疗策略提供数据.
主要方法:
- 一个2a/b期,随机,双盲,安慰剂控制,多中心试验.
- 患有ARDS的患者接受了吸入PEG-ADM (960微克或1920微克) 或安慰剂.
- 主要终点包括安全性,疗效 (无呼吸器生存率,临床效用指数) 和28日结果.
主要成果:
- 在PEG-ADM和安慰剂组中随机分配了90名患者.
- PEG-ADM表现出耐受性良好的安全性,与安慰剂可比.
- 没有观察到临床效用指数的显著改善;没有增强无呼吸器生存率.
结论:
- 吸入PEG-ADM对在机械通风中接受ARDS患者来说是安全的.
- 该研究没有证明PEG-ADM在改善ARDS临床结果方面的有效性.
- 该试验因徒劳而提前中止,表明缺乏治疗益处.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
457
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
457
Inhaled Medications
735
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
735
COPD: Management Using Bronchodilators and Corticosteroids
722
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
722
Antiasthma Drugs: β2-Adrenoceptor Agonists
1.6K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
1.6K
